Loading clinical trials...

UNKNOWNNA

Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System

NCT05549414•P-Cure

Summary

This study with Chair-Based, Gantry-less Proton System (CBGS) (aka P-CURE Proton Beam Therapy System or Fixed Beam Chair-based Delivery System) is composed of 3 arms, as following: ARM1: Patients with locally recurrent, previously irradiated thoracic cancer indicated for re- irradiation. ARM2: Patients with recurrent Head and Neck, Brain and Spinal Cord tumors, indicated for re- irradiation. ARM3: Patients with unresectable pancreatic cancer. The primary objectives of the study for all arms are: 1. to describe the efficacy (local control after 3 month) and acute toxicity for patients treated with a fully-integrated CBGS and (2) to compare treatment plans between the fully-integrated CBGS and Photon therapy defined for each patient, based upon OAR sparing for comparable target coverage.

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Pathologically (histologically or cytologically) proven malignancy
•Treatment planning analysis shows advantage to proton over photon treatments
•both malignancies (such as thoracic tumors) as well as metastatic lesions (such as metastatic breast cancer or colorectal cancer to the lungs) are allowed
•Patient must have CT confirmation of the tumor
•Patients must have a life expectancy of \> 6 months
•Patients must have measurable disease to be treated with proton radiation (minimum tumor dimension at least 10 mm on CT imaging).
•Patients must be a candidate for definitive radiation dose
•There are no limits on prior therapy. Patients are allowed to have prior chemotherapy and surgery. Patients are allowed to have concurrent chemotherapy with radiation treatment. Patients are allowed to have chemotherapy or surgery after radiation treatment

Exclusion Criteria

•1. Severe, active co-morbidity, defined as follows:
•1. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
•2. Transmural myocardial infarction within the last 6 months
•3. Chronic obstructive pulmonary disease exacerbation or other respiratory illness other than the diagnosed lung cancer requiring hospitalization or precluding study therapy within 30 days before registration
•4. Acquired immune deficiency syndrome (AIDS) based upon current CDC definition (protocol may be significantly immunosuppressive endangering AIDS patients)
•2. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
•3. Patients with life expectancy \< 6 months
•4. Patients that participate in another, active clinical trial carried out concurrently with this protocol

Locations (1)

Hadassah Ein Karem

Jerusalem, Israel

Key Dates

Start Date

March 30, 2023

Primary Completion Date

January 1, 2025

Completion Date

February 1, 2026

Last Updated

July 10, 2023

Enrollment

100

ESTIMATED participants

Conditions

Thoracic CancerPancreatic Cancer Non-resectableBrain CancerHead CancerNeck Cancer

Interventions

Proton Radiation

DEVICE

Contacts

Irena Barsky

CONTACT

0534304994 irab@hadassah.org.il

Ori Lubin

CONTACT

0544881399 ori.lubin@p-cure.com

Erector Spinae Block for Thoracic Surgery

NCT05521789

Pulmonary NeoplasmPulmonary Cancer+3 more

View study

RECRUITINGPHASE1/PHASE2

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT06922591

PDACPDAC - Pancreatic Ductal Adenocarcinoma+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 10, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System

Inclusion Criteria

Exclusion Criteria

Erector Spinae Block for Thoracic Surgery

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer

Evaluation of On-Couch CBCT Image Quality